Insider Trading Alert - PMC, JAZZ And EA Traded By Insiders

Stocks with insider trader activity include PMC, JAZZ and EA
By TheStreet Wire ,

Yesterday, Nov. 12, 2015, 171 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $70,050,500.00.

Highlighted Stocks Traded by Insiders:

Pharmerica (PMC) - FREE Research Report

Lindemoen Mark, who is SVP Sales and Client Services at Pharmerica, sold 3,790 shares at $34.71 on Nov. 12, 2015. Following this transaction, the SVP Sales and Client Services owned 18,009 shares meaning that the stake was reduced by 17.39% with the 3,790-share transaction.

The shares most recently traded at $34.96, up $0.25, or 0.72% since the insider transaction. Historical insider transactions for Pharmerica go as follows:

  • 4-Week # shares sold: 7,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares sold: 115,180

The average volume for Pharmerica has been 203,000 shares per day over the past 30 days. Pharmerica has a market cap of $1.0 billion and is part of the services sector and wholesale industry. Shares are up 64.17% year-to-date as of the close of trading on Thursday.

PharMerica Corporation operates as an institutional pharmacy services company in the United States. The company offers services to healthcare facilities; pharmacy management services to hospitals; specialty infusion services to patients outside hospitals; and oncology pharmacy services. Currently, there are 5 analysts who rate Pharmerica a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PMC - FREE

TheStreet Quant Ratings

rates Pharmerica as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full

Pharmerica Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Cozadd Bruce C, who is Chairman & CEO at Jazz Pharmaceuticals, sold 2,500 shares at $128.53 on Nov. 12, 2015. Following this transaction, the Chairman & CEO owned 289,355 shares meaning that the stake was reduced by 0.86% with the 2,500-share transaction.

The shares most recently traded at $135.91, up $7.38, or 5.43% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 7,625
  • 24-Week # shares sold: 26,357

The average volume for Jazz Pharmaceuticals has been 747,300 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $8.3 billion and is part of the health care sector and drugs industry. Shares are down 18.15% year-to-date as of the close of trading on Thursday.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 25.9. Currently, there are 10 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings

rates Jazz Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, good cash flow from operations, expanding profit margins and impressive record of earnings per share growth. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Jazz Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Electronic Arts (EA) - FREE Research Report

Linzner Joel, who is EVP Legal & Business Affairs at Electronic Arts, sold 4,000 shares at $72.19 on Nov. 12, 2015. Following this transaction, the EVP Legal & Business Affairs owned 114,948 shares meaning that the stake was reduced by 3.36% with the 4,000-share transaction.

The shares most recently traded at $70.87, down $1.32, or 1.86% since the insider transaction. Historical insider transactions for Electronic Arts go as follows:

  • 4-Week # shares sold: 67,279
  • 12-Week # shares sold: 123,061
  • 24-Week # shares sold: 250,788

The average volume for Electronic Arts has been 3.2 million shares per day over the past 30 days. Electronic Arts has a market cap of $22.2 billion and is part of the technology sector and computer software & services industry. Shares are up 52.42% year-to-date as of the close of trading on Thursday.

Electronic Arts Inc. develops, markets, publishes, and distributes game software content and online services for video game consoles, Internet-connected consoles, personal computers, mobile phones, and tablets worldwide. The company operates through EA Studios, EA Mobile, and Maxis divisions. The company has a P/E ratio of 28.1. Currently, there are 13 analysts who rate Electronic Arts a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EA - FREE

TheStreet Quant Ratings

rates Electronic Arts as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Electronic Arts Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...